Study Summary
This trial compares effects of two chemo drugs to treat rectal cancer after radiation therapy. Results may help avoid surgery for some patients.
- Rectal Cancer
- Stage III Rectal Cancer
- Stage II Rectal Cancer
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 5 Secondary · Reporting Duration: Up to 5 years
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
2 Treatment Groups
Group I (LCRT, FOLFOX or CAPOX)
1 of 2
Group II (LCRT, FOLFIRINOX)
1 of 2
Active Control
Experimental Treatment
312 Total Participants · 2 Treatment Groups
Primary Treatment: Group II (LCRT, FOLFIRINOX) · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are applications for participation in this experiment being accepted at present?
"Affirmative. Clinicaltrials.gov publicly states that this trial began its recruitment phase on December 8th 2022 and was last updated on January 4th 2023. This initiative is searching for a total of 312 participants from 2 distinct sites to participate in the study." - Anonymous Online Contributor
What is the cap for enrollment in this clinical experiment?
"Affirmative, the clinical trial is open for enrollment according to information found on clinicaltrials.gov - which was last updated on January 4th 2023. This study requires 312 individuals from 2 different sites and first posted online December 8th 2022." - Anonymous Online Contributor
Has the United States Food and Drug Administration sanctioned Group II (LCRT, FOLFIRINOX) for therapeutic use?
"Taking into consideration the Phase 2 status of Group II (LCRT, FOLFIRINOX), our team assigned it a safety score of 2 due to existing evidence supporting its security though no studies have proven effectiveness." - Anonymous Online Contributor